Mr. Steve Loutskou reports

RESTART LIFE CLOSES OVER-SUBSCRIBED SECOND TRANCHE FINANCING

Further to the news release dated Nov. 12, 2025, and Dec. 5, 2025, Restart Life Sciences Corp. has closed the oversubscribed second tranche of its non-brokered private placement for total gross proceeds of $630,000. As announced on Nov. 12, 2025, the company intended to raise a total of up to $1-million; however, due to overwhelming interest in the company's objectives, the company has raised a total of $1.13-million in two tranches.

Pursuant to the second tranche of the private placement, the company has allotted and issued 6.3 million units at a price of 10 cents per unit. Each unit consists of one common share and one transferable common share purchase warrant. Each warrant entitles the holder to purchase one additional common share for a period of one year at a price of 10 cents per common share.

In connection with the placement, the company issued 132,000 non-transferable finder warrants to certain eligible arm's-length finders which introduced subscribers to the placement. Each finder warrant entitles the holder to purchase one common share for a period of one year at a price of 10 cents per common share.

The company intends to use the proceeds from the offering toward health food trials, potential acquisitions and general working capital. All securities issued under the placement are subject to a hold period of four months and one day expiring on April 18, 2026.

About Restart Life Sciences Corp.

Restart is a Canadian-based life science company listed on the Canadian Securities Exchange.

We seek Safe Harbor.